Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
It is our mission to be the go-to leaders in the aviation industry. GlobalAir.com is your partner in connecting you with relevant information and resources.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback